QQ客服 官方微博 反馈留言

	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
	Jiang, Zefei; Li, Wei; Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Cui, Shude; Wang, Shusen; Ouyang, Quchang; Yin, Yongmei; Geng, Cuizhi
刊名	LANCET ONCOLOGY
	2019
卷号	20期号:6
ISSN号	1470-2045
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3597822
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Jiang, Zefei,Li, Wei,Hu, Xichun,et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. LANCET ONCOLOGY,2019,20(6).
APA	Jiang, Zefei.,Li, Wei.,Hu, Xichun.,Zhang, Qingyuan.,Sun, Tao.,...&Lu, Xianping.(2019).Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.LANCET ONCOLOGY,20(6).
MLA	Jiang, Zefei,et al."Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial".LANCET ONCOLOGY 20.6(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。